Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type. b- E& X a W+ l! ?9 q; a
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 0 h! H9 i3 i' N+ r) P
+ Author Affiliations
3 n: H, j- S1 S7 l- e7 W: |7 D. E5 D9 r+ ?4 N
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan : a6 a0 M* q# Z# N, w0 }' d
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 1 J$ a, P3 x8 a, F7 M$ o
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
: V; b! I8 Z P8 Z! j- m5 L& e0 I4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
1 a# A4 l' m& k3 O& z5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan & b. Y' P( q1 W0 T j: z8 B
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
8 S) }; y S1 j2 j: F. r7Kinki University School of Medicine, Osaka 589-8511, Japan % |5 h( \ _1 C6 }, y+ [# @) x2 _4 w
8Izumi Municipal Hospital, Osaka 594-0071, Japan 4 A' D ?8 g1 j3 q
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan / B# F& Z y. x+ k; m$ R
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp n# j. w- ]: E* B! x$ `7 z$ e* `
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 5 E7 G5 Q a, h g, K# z% i* p& M. w: \
( m0 H* P- d. _6 q( P, U P2 z( i |